| Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand (NCT05753150) | Dr. Prayuth Sudathip | 2022-05-23 |
| Plasmodium Vivax Among Duffy Negative Population in Cameroon. (NCT05058885) | University of Dschang | 2022-05-02 |
| Serological Screen and Treat Trial for Plasmodium Vivax (NCT04223674) | Indonesia University | 2022-02-09 |
| Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine (NCT05270265) | University of Oxford | 2022-02-09 |
| Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil (NCT05096702) | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | 2021-09-09 |
| Study to Evaluate Primaquine for Radical Cure of Uncomplicated Plasmodium Vivax Malaria in Children (NCT05044637) | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | 2021-08-26 |
| Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers (NCT04739917) | Malaria Vaccine and Drug Development Center | 2021-06-01 |
| Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine (NCT04411836) | Menzies School of Health Research | 2021-04-25 |
| Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria (NCT04709692) | R. Kiplin Guy | 2021-04-14 |
| Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1 (NCT04201431) | University of Oxford | 2020-01-24 |
| VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines (NCT04009096) | University of Oxford | 2019-07-18 |
| Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua (NCT06036030) | Syamsudin Abdillah,Ph.D, Pharm D | 2019-01-11 |
| VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection (NCT03797989) | University of Oxford | 2019-01-10 |
| DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil (NCT03208907) | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | 2018-07-05 |
| Assessing a Risk Model for G6PD Deficiency (NCT03337152) | PATH | 2018-05-07 |
| Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil (NCT03610399) | Centers for Disease Control and Prevention | 2018-04-09 |
| Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria (NCT02802501) | GlaxoSmithKline | 2018-04-08 |
| Study of Controlled Human Plasmodium Vivax Infection (NCT03377296) | University of Oxford | 2018-03-03 |
| A Retrospective Study of Severe Plasmodium Vivax (NCT03307369) | University of Oxford | 2017-10-27 |
| A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria (NCT02563496) | GlaxoSmithKline | 2017-02-06 |
| A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution (NCT02751294) | GlaxoSmithKline | 2016-05-01 |
| Assessment of Any Potential Retinal Effects of Tafenoquine (TQ) (NCT02658435) | GlaxoSmithKline | 2016-02-02 |
| Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria (NCT02216123) | GlaxoSmithKline | 2015-04-30 |
| Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection (NCT02691910) | Oswaldo Cruz Foundation | 2014-08-01 |
| A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate (NCT02184637) | GlaxoSmithKline | 2014-07-31 |
| Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria (NCT02110784) | Alfasigma S.p.A. | 2014-06-18 |
| Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse (NCT01376167) | GlaxoSmithKline | 2014-04-24 |
| Tafenoquine Thorough QTc Study in Healthy Subjects (NCT01928914) | GlaxoSmithKline | 2011-07-26 |
| Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection (NCT01213966) | Medicines for Malaria Venture | 2010-10-01 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects (NCT00928083) | Medicines for Malaria Venture | 2009-04-01 |
| Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax (NCT00811096) | Walter Reed Army Institute of Research (WRAIR) | 2008-11-01 |
| A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia. (NCT00157885) | Menzies School of Health Research | 2005-07-01 |
| Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria (NCT00486694) | London School of Hygiene and Tropical Medicine | 2004-03-01 |
| Therapeutic Efficacy Study of Pyrimethamine/Sulfdoxine (Fansidar®) for the Treatment of Uncomplicated Falciparum Malaria in the Peruvian Amazon (NCT00951106) | Walter Reed Army Institute of Research (WRAIR) | 1998-01-01 |